Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyvox, Synercid Launches Indicate Market Receptivity To New Antibiotics

Executive Summary

Pharmacia's Zyvox (linezolid) sales of $19 mil. in the two-and-a-half months from its U.S. commercial launch in mid-April until the end of the June 30 quarter put the product $4 mil. ahead of sales of the Aventis antibiotic Synercid (quinipristin/dalfopristin) in the second quarter of 2000.

You may also be interested in...



Cubist Cidecin NDA For Mid-2002; Launch Will Need Up To 150 Reps, CEO Says

Cubist's will file an NDA for its intravenous antibiotic Cidecin (daptomycin) in mid-2002, CEO Scott Rocklage told analysts during Bear Stearns' "virtual" healthcare conference Sept. 24.

Cubist Cidecin NDA For Mid-2002; Launch Will Need Up To 150 Reps, CEO Says

Cubist's will file an NDA for its intravenous antibiotic Cidecin (daptomycin) in mid-2002, CEO Scott Rocklage told analysts during Bear Stearns' "virtual" healthcare conference Sept. 24.

Cubist Changes Internet Press Release Policy After FDA Letter On Daptomycin

Cubist Pharmaceuticals will purge press releases from its website after six months in response to a Nov. 22 letter from FDA maintaining that Cubist's press releases available on the Internet amount to pre-approval promotion of Cidecin (daptomycin).

Related Content

UsernamePublicRestriction

Register

PS036483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel